Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2000-11-13
2004-02-24
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C264S004100, C264S004300
Reexamination Certificate
active
06696080
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to liposomal bupivacaine compositions, useful for long term analgesia, which are prepared using an ammonium sulfate gradient loading procedure. The invention also provides methods of providing analgesia using such formulations. Also disclosed are liposome suspensions comprising ‘GMV’ (giant multivesicular) liposomes and methods for their preparation.
REFERENCES
Boogaerts, J. G. etal.; Can J Anaesth 40(12):1201-1204 (1993).
Grant, G. J. et al., Reg Anesth 19(4):264-269 (1994).
Haran, G. et al., Biochem Biophys Acta 1151(2):201-215 (1993).
Kim, S. et al., U.S. Pat. No. 5,723,137 (1998).
Legros, F. et al., U.S. Pat. No. 5,244,678 (1993).
Mowat, J. J. et al., Anesthesiology 85(3):635-643 (1996).
Stewart, J.C.M., Anal. Biochem. 104, 10 (1959).
BACKGROUND OF THE INVENTION
Liposomal encapsulation of local anesthetics has been shown to increase the duration of pain relief. Critical factors in the effectiveness of liposomal bupivacaine formulations include encapsulation of the maximal amount of drug, as well as a suitable release rate after injection. The primary disadvantages of previously described liposomal bupivacaine formulations (e.g. Boogaerts, Grant, Legros) are relatively inefficient drug entrapment and low drug/lipid ratios. This can lead to an undesirable deposit of fatty lipid material at the site of injection.
Recently, active loading of bupivacaine using a pH gradient was described (Mowat). A sodium citrate solution was used to establish a transmembrane gradient, and a drug/lipid ratio of 0.26 was achieved, higher than that obtained previously via standard “passive” loading techniques (e.g. Legros). However, in Mowat, the extraliposomal pH was maintained at about 7.4, which potentially limits the amount of drug available for loading, as bupivacaine is poorly soluble at this pH.
SUMMARY OF THE INVENTION
The present invention includes, in one aspect, a method of producing prolonged analgesia by administering a liposomal bupivacaine composition. The composition is prepared by incubating a bupivacaine solution with a suspension of liposomes having a greater concentration of ammonium ions inside said liposomes than outside said liposomes. Such a suspension is prepared by (a) vortexing a lipid film with an aqueous solution of ammonium sulfate and (b) removing ammonium sulfate from the extraliposomal medium. Preferably, the aqueous solution has a concentration of about 250 mM ammonium sulfate, and, in the incubating step, the bupivacaine solution has a pH effective to prevent precipitation of the bupivacaine; typically about 6 or less.
The method of administering of the local anesthetic compositions may also comprise cooling of the administration site. Preferably, the skin of the subject is cooled to a temperature of about 22° C. at the site of injection.
In a preferred embodiment, the liposomes are ‘GMV’ (giant multivesicular) liposomes. These are prepared by (a) vortexing a lipid film with an aqueous solution, such as a solution of ammonium sulfate, (b) homogenizing the resulting suspension to form a suspension of small unilamellar vesicles (SUV), and (c) repeatedly freeze-thawing said suspension of SUV in liquid nitrogen followed by water. Preferably, the freeze-thawing is repeated at least five times, and more preferably about ten times. The extraliposomal ammonium sulfate is then removed, e.g. by dialysis against normal saline. The GMV liposomes, and the disclosed method of preparation, provide additional aspects of the present invention. Preferably, the method of preparation includes encapsulating a therapeutic substance within the liposomes, e.g. by incubating a suspension of the liposomes with a solution of the therapeutic substance. Preferably, the substance is weakly basic, and the suspension of GMV liposomes has a greater concentration of ammonium ions inside the liposomes than outside the liposomes, as described above. Where the substance is bupivacaine, in the incubating step, the bupivacaine solution has a pH effective to prevent precipitation of the bupivacaine; typically about 6 or less.
The GMV-based liposomal bupivacaine compositions typically have a molar drug to lipid ratio, following removal of non-encapsulated bupivacaine, of at least 1.0. After further concentration of the resulting liposomal suspension by ultrafiltration or centrifugation, the a molar drug to lipid ratio is at least 0.5, preferably at least 1.0, and more preferably at least 1.5.
REFERENCES:
patent: 4532089 (1985-07-01), MacDonald
patent: 5188837 (1993-02-01), Domb
patent: 5192549 (1993-03-01), Barenholz et al.
patent: 5244678 (1993-09-01), Legros
patent: 5316771 (1994-05-01), Barenholz et al.
patent: 5723137 (1998-03-01), Wahle et al.
patent: 0 233 100 (1987-08-01), None
patent: 0 361 894 (1990-04-01), None
patent: 98 14171 (1998-04-01), None
Weiner, Drug Development and Industrial pharmacy, 15, (10), pp. 1523-1554, 1989.*
Haran in BBA vol. 1151, pp 201-215 1993.*
Antimisiaris et al., “Liposomes as vaccine carriers Incorporation of soluble and particulate antigens in giant vesicles”,Journal of Immunological Methods, (1993), vol. 166, pp. 271-280.
Masters et al., “Liposphere Local Anesthetic Timed-Released for perineural Site Application”,Pharmaceutical Research, (1998), vol. 15, No. 7, pp. 1038-1045.
Mayer et al., “Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles”,Biochimica et Biophysica Acta, (1985), vol. 817, pp. 193-196.
Mowat et al., “Liposonnal Bupivacaine, Extended Duration Nerve Blockage Using Large Unilamellar Vesicles that Exhibit a Proton Gradient”,Anesthesiology, (1996), vol. 85, pp. 635-843.
Turski et al., “Magnetic Resonance Imaging of Rabbit Brain after Intracarotid Injection of Large Multivesocular Lipsomes Containing Paramagnetic Metals and DTPA”,Magnetic Resonance in Medicine, (1988), vol. 7, pp. 184-196.
Pick, “Liposomes with a Large Trapping Capacity prepared by Freezing and Thawing of Sonicated Phospholipid Mixtures”,Archives of Biochemistry and Biophysics, (1981), vol. 212, No. 1, pp. 186-194.
Abstract of Boogaerts, et al., “Plasma concentrations of bupivacaine after brachial plexus administration of liposome-associated and plain solutions to rabbits.”Can. J. Anaesth. 40(12):1201-1204 (1993).
Abstract of Grant, et al., “Prolonged analgesia with liposomal bupivacaine in a mouse model.”Reg. Anesth.19(4):264-269 (1994).
Mowat, et al., “Liposomal Bupivacaine.”Anesthesiology85:635-643 (1996).
Haran, et al., “Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.”Biochimia et Biophysica Acta1151:201-215 (1993).
Stewart, John, “Colormetric Determination of Phospholipids with Ammonium Ferrothiocyanate”, Analytical Biochemistry, vol. 104, 1980, pp. 10-14.
Barenholz Yechezkel
Bolotin Elijah M.
Grant Gilbert J.
Piskoun Boris
Turndorf Herman
Browdy and Neimark , P.L.L.C.
Kishore Gollamudi S.
Yissum Research Development Company of the Hebrew University of
LandOfFree
Liposomal bupivacaine compositions prepared using an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liposomal bupivacaine compositions prepared using an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal bupivacaine compositions prepared using an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3322122